Join us for a virtual R&D and Investor Day, featuring John Teerlink, MD (University of California, San Francisco) who will discuss the unmet medical need and current treatment landscape for patients suffering from cardiogenic shock and severe heart failure, a cardiovascular condition with high morbidity, mortality and unmet need. Dr. Teerlink will also provide perspective on the latest innovation and the role of istaroxime.

Members of our leadership team will provide insight into our strategy and recently enhanced plans with our lead candidate istaroxime, a first in class, dual-acting agent, being developed to treat cardiogenic shock and acute decompensated heart failure; and the multiple short-term milestones the Company expects to achieve. Company strategy, including business development, will also be presented.

A live question and answer session will follow the formal presentations.